Both terms, both drugs, and the amount actually billed
Each product page gives a month-to-month figure in the body and a three-month figure in the FAQ, and for tirzepatide it states the amount charged every three months rather than only the per-month equivalent. That amount divided by three is a fraction more than the figure the seller prints; the rounding is downward and small.
Stating the billed amount at all puts this seller ahead of most of the roster, where a per-month equivalent is published and the actual charge is not.
The title and the page disagree about the headline
The browser title for the semaglutide page advertises the three-month rate. The page body leads with the month-to-month rate, which is higher. Both are the seller's own figures and both are true of the plan they describe.
A reader arriving from a search result sees the lower number first and the higher one second. Our record carries the month-to-month figure as the price row, because it is the rate that holds without a commitment, and the qualifier carries the other.
Who prescribes, and under which suffix
The Terms and the Privacy Policy both state that care is provided by independently licensed providers through a named clinical group. That group also stands behind several other sellers on this roster, which is worth knowing if you are comparing them as independent operations.
The same document names the group as a professional association in one clause and a professional corporation in another. Both are recorded and neither is treated as the correct one.
Naming a clinical entity is not naming a clinician. One hundred and eight of the one hundred and fifty-eight sellers here name nobody who prescribes, and this is one of them. The compounding pharmacies are described as a network of licensed US compounders rather than named.
Vytora Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $179/mothe month-to-month rate; the same page prices a three-month plan at $149 a month, and the page title advertises the lower of the two | September 2026source |
| Tirzepatide (compounded) | $249/mothe month-to-month rate; the three-month plan is quoted at $199 a month billed $599 every three months, and $599 divided by three is $199.67, which the seller rounds down | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Vytora Health's current price →Good fit if
- Buyers deciding between a monthly commitment and a quarterly one with both figures published.
- Readers who want the amount actually charged, not only a per-month equivalent.
- People comparing several sellers that share one clinical group and want to know which ones they are.
Look elsewhere if
- Anyone who wants an individual prescriber named.
- Buyers who need the compounding pharmacy named.
- Readers who need a service-area list.
- People who want the page and its title to advertise the same figure.
How this review was verified
- Read both product pages, the Terms and the Privacy Policy on 6 September 2026, with a nonsense-path control on the host in the same run.
- Divided the stated quarterly charge by three rather than repeating the seller's per-month figure, and recorded the difference.
- Recorded the clinical group under both suffixes it is given, in the same document, without choosing between them.
- Compared the browser title against the page body and recorded that they lead with different figures.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.